Deep Experience

There is no substitute for four decades of biologics experience

At Amgen, we specialize in unlocking the potential of biology to create new ways to combat the most difficult diseases, to better serve patients. We have been steeped in this challenge since the early days of recombinant DNA technology, when a handful of scientists and investors came together to prove the promise of innovative biotechnology.

One of our first big discoveries came in 1983. For 2 years, a team led by a young scientist named Fu-Kuen Lin had combed tirelessly through 1.5 million fragments of the human genome before isolating and cloning the erythropoietin gene, which is responsible for the stimulation of red blood cell production.1 This discovery ultimately set the future direction of our company.2

One of the first companies to develop3-5:

  • Therapeutic proteins, which replace or augment beneficial human proteins
  • Monoclonal antibodies, therapeutic proteins that target disease with specificity





These therapies have been used to treat millions of patients around
the world, and there’s an opportunity to help treat millions more with Amgen’s
growing portfolio of biosimilars, both approved and in the pipeline.

Biology first—and foremost

Amgen was one of the first large-scale biotechnology manufacturers, and we’re now one of the largest independent biotechnology companies. We have developed some of the most widely used, high-quality biologic medicines, with a portfolio totaling more than a dozen medicines across six therapeutic areas: oncology and hematology, cardiovascular disease, nephrology, inflammation, bone health, and neuroscience.6

Each step of the way, we’ve refined our biotechnological processes and expertise. Our long experience developing and refining our systems ensures we can provide a reliable supply of our biologic medicines worldwide.7

More recently, we have used human genetic validation whenever possible in the discovery and development process to6,8:

  • Pursue a “biology-first” approach to drug discovery—selecting drug targets with a deep understanding of disease biology and then choosing a drug modality, or structural template, best suited to the target
  • Maintain the industry's leading toolkit of modalities, which allows us to select the optimal tool to target the key molecular defect

Amgen's “biology-first” approach coupled with an array of drug modalities carries several benefits:

Enhanced likelihood of success

Efficient development of new medicines

Increased patient options to new medicines

Many things at Amgen remain unchanged from those early years. We still operate with the same drive, determination, and innovative spirit and values—finding ways to transform new ideas and discoveries, to make life better for millions of patients.

Biosimilar standards born of our
biologics standards

One of our most exciting pursuits is the exploration of biosimilar medicines, which will offer new treatment options for physicians and patients. We are taking our rich biologic experience and putting everything we’ve learned into making high-quality biosimilar medicines. Not only that, we’re backing it all with our established reputation for quality, reliability, and support services.9

References: 1. National Center for Biotechnology Information. EPO erythropoietin [Homo sapiens (human)]. Accessed April 16, 2018. 2. 2004 Annual Report. Thousand Oaks, CA: Amgen, Inc.; December 2004. 3. Lybecker KM. The biologics revolution in the production of drugs. Fraser Institute. Accessed April 25, 2018. 4. Nowicki M. Basic facts about biosimilars. Kidney Blood Press Res. 2007;30:267-272. 5. Rugo HS, Linton KM, Cervi P, Rosenberg JA, Jacobs I. A clinician's guide to biosimilars in oncology. Cancer Treat Rev. 2016;46:73-79. 6. Amgen. Amgen Unlocking the Potential of Biology for Patients. Accessed April 25, 2018. 7. Data on file, Amgen; 2018. 8. Amgen. The Shape of Drugs to Come. Published September 19, 2017. Accessed May 5, 2018. 9. Amgen Press Release. Amgen Continues Manufacturing Expansion with Additional $1 Billion Investment in Puerto Rico.­-manufacturing-expansion-with-additional-$1-billion-investment-in-puerto-rico/. Published February 2006. Accessed April 24, 2018.

Next: Worldwide Biologics Leader